Related Experiment Video

Updated: Jan 3, 2026

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

19.2K

The cyclin‑dependent kinase pathway involving CDK1 is a potential therapeutic target for cholangiocarcinoma

Minako Yamamura1, Yasunori Sato1, Kenta Takahashi1

  • 1Department of Human Pathology, Kanazawa University Graduate School of Medicine, Kanazawa 920‑8640, Japan.

Oncology Reports
|November 21, 2019
PubMed

Insights

Targeting cyclin-dependent kinase (CDK) pathways, specifically CDK1, shows promise for treating cholangiocarcinoma. This study found elevated CDK pathway markers in tumors, and the inhibitor roscovitine reduced cancer growth and induced cell death.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Cholangiocarcinoma (CCA) is an aggressive bile duct cancer with limited treatment options.
  • The role of cyclin-dependent kinase (CDK) pathways in CCA pathogenesis and progression is not well understood.
  • Identifying novel therapeutic targets is crucial for improving CCA patient outcomes.

Purpose of the Study:

  • To investigate the biological significance of CDK pathways in cholangiocarcinoma.
  • To evaluate the therapeutic potential of CDK inhibition in CCA.
  • To explore the prognostic value of CDK pathway markers in CCA.

Main Methods:

  • Immunohistochemical analysis of CDK pathway proteins (p-CDK1, p-CDK2, cyclin B1, cyclin E1) in CCA tissues.
  • In vitro studies using CCA cell lines treated with the multi-CDK inhibitor roscovitine.
  • In vivo studies using a murine xenograft model treated with roscovitine.

Main Results:

  • Upregulated expression of p-CDK1, p-CDK2, cyclin B1, and cyclin E1 was observed in CCA cells.
  • Nuclear expression of p-CDK1 and cyclin B1 correlated with lymph node metastasis, clinical stage, and poor survival.
  • Roscovitine treatment decreased p-CDK1, inhibited proliferation, induced cell cycle arrest, reduced invasion, and promoted apoptosis in CCA cells both in vitro and in vivo.

Conclusions:

  • The CDK pathway, particularly involving CDK1, represents a potential therapeutic target for cholangiocarcinoma.
  • Inhibition of CDK pathways with agents like roscovitine demonstrates anti-cancer effects in CCA.
  • Immunohistochemical detection of p-CDK1 may serve as a valuable prognostic biomarker for cholangiocarcinoma.
Keywords:
cholangiocarcinomacyclin-dependent kinasecell cyclechemotherapyprognosis

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.7K
Experimental Approaches to Study Mitochondrial Localization and Function of a Nuclear Cell Cycle Kinase, Cdk113:15

Experimental Approaches to Study Mitochondrial Localization and Function of a Nuclear Cell Cycle Kinase, Cdk1

Published on: February 25, 2016

12.3K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.4K
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
133.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.3K